etoposide oral / Generic mfg. - LARVOL DELTA

Randomized phase II trial of maintenance oral etoposide versus observation following high-dose chemotherapy and peripheral blood stem cell transplant in relapsed non-seminomatous germ cell tumors. (ASCO-GU 2026) - P2 | "Eligible patients are adults with metastatic NSGCT who have experienced progression after first-line cisplatin-based chemotherapy. All participants will complete two tandem cycles of HDCT using the Indiana carboplatin/etoposide protocol...Accrual and follow-up are ongoing. Clinical trial information: NCT04804007."

Clinical • P2 data • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Non-seminoma • Testicular Seminoma

Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT). (ASCO-GU 2026) - P1/2 | "Background: While most patients (pts) with metastatic GCTs are cured with first line cisplatin-based chemotherapy, 20-30% relapse after treatment. This study is currently enrolling patients. Clinical trial information: NCT06937866."

Clinical • Metastases • Genito-urinary Cancer • Germ Cell Tumors • Oncology • Testicular Cancer • AXL • KDR • MET

Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study. (PubMed, BMC Cancer) - P2 | "The combination of pyrotinib with metronomic oral etoposide has achieved promising clinical benefits in heavily pretreated HER2-positive MBC, with acceptable and manageable toxicity."

Journal • Metastases • P2 data • Breast Cancer • Hematological Disorders • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Pain • Solid Tumor • HER-2

Is there a role for oral etoposide (VP-16) maintenance following high-dose chemotherapy (HDCT) in metastatic germ cell tumors (GCT)? (IGG-04) (ESMO 2026) - No abstract available

Clinical • Metastases • Germ Cell Tumors • Oncology

Etoposide as Late-Line Therapy for Metastatic Extramammary Paget's Disease: A Case Series. (PubMed, J Dermatol) - "Agents such as docetaxel, cisplatin, and 5-fluorouracil have been used, but evidence supporting their efficacy remains limited. Although all patients eventually died from disease progression, etoposide provided disease control and symptomatic relief. These findings suggest that oral etoposide may represent a feasible and relatively well-tolerated late-line treatment option for metastatic EMPD."

Journal • Alopecia • Hematological Disorders • Immunology • Neutropenia • Oncology • Rare Diseases • Skin Cancer • CEACAM5

Successful Treatment of Adult Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis With Etoposide Guided by Plasma Epstein-Barr Virus DNA Monitoring: A Case Report. (PubMed, EJHaem) - "Initial treatment with methylprednisolone and cyclosporine A was followed by weekly oral etoposide, with careful monitoring in the setting of severe hepatic dysfunction. This case suggests that timely etoposide-based therapy may be feasible in severe EBV-HLH when response and toxicity are carefully monitored. The authors have confirmed clinical trial registration is not needed for this submission."

Journal • Epstein-Barr Virus Infections • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Hepatology • Immunology • Infectious Disease • Liver Failure • Rare Diseases

Focused ultrasound blood-brain-barrier opening with etoposide in pediatric diffuse midline glioma (ISPNO 2026) - "Following the withdrawal of panobinostat from the market, the study re-opened using oral etoposide as replacement, based on preclinical evidence suggesting Topoisomerase II as an actionable target in DMG. Early results indicate that FUS-mediated BBB disruption for drug delivery in pediatric DMG is feasible and well tolerated, though with varying outcomes."

Clinical • Brain Cancer • Diffuse Midline Glioma • Glioma • Pediatrics • Solid Tumor

Phase I/II trial of axitinib and etoposide in children with refractory or relapsed medulloblastoma or ependymoma: MEPENDAX report (ISPNO 2026) - " Patients received axitinib twice daily and oral etoposide at 25 mg/m²/day once daily in 28-day cycles for up to 13 cycles. The combination of axitinib and etoposide currently demonstrated acceptable tolerability in children with refractory or relapsed medulloblastoma or ependymoma. The RP2D will be established, and ongoing phase II enrollment will provide definitive efficacy data."

Clinical • P1/2 data • Brain Cancer • Ependymoma • Hematological Disorders • Medulloblastoma • Neutropenia • Oncology • Solid Tumor

High risk medulloblastoma in children older than four years old: A prospective analysis of outcome with craniospinal radiation and metronomic therapy (ISPNO 2026) - " This prospective study included patients treated with CSI (36 Gy) with concomitant carboplatin, followed by cisplatin/cyclophosphamide-based maintenance CT and one year of metronomic therapy (oral etoposide, cyclophosphamide, fenofibrate, and celecoxib). Children with HR-MB treated with CSI, maintenance chemotherapy, and metronomic therapy demonstrated encouraging survival outcomes. These findings suggest a potential role for metronomic chemotherapy in improving survival in selected subgroups of this high-risk population"

Clinical • Brain Cancer • Medulloblastoma • Solid Tumor • MYC • MYCN

Primary tonsillar kaposi sarcoma in an HIV-negative, immunocompetent patient: A case-based review. (PubMed, Ir J Med Sci) - "Primary tonsillar Kaposi sarcoma in HIV-negative, immunocompetent patients is an extremely rare clinical entity but should be considered in the differential diagnosis of tonsillar masses. HHV-8 immunostaining is essential for accurate diagnosis. Surgical excision, combined with systemic and local therapies for recurrence, can provide durable disease control. Long-term follow-up is crucial due to the potential for late multifocal recurrence."

Journal • Review • Epstein-Barr Virus Infections • Human Immunodeficiency Virus • Infectious Disease • Kaposi Sarcoma • Oncology • Sarcoma • Solid Tumor

Real-World Evidence of Treatment Patterns, Time to Real-World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States. (PubMed, Cancer Med) - "Real-world data captured heterogeneous treatment patterns and poor outcomes for patients with R/R testicular GCT receiving palliative chemotherapy, highlighting the need for novel therapies."

HEOR • Journal • Real-world evidence • Germ Cell Tumors • Oncology • Palliative care • Testicular Cancer

Toxicity and efficacy of four carmustine-substituted conditioning regimens followed by autologous stem cell transplantation in lymphoma: a real-world comparative study. (PubMed, Ann Hematol) - "Patients received one of four regimens: BeEAM (bendamustine, etoposide, cytarabine, melphalan; n = 16), CBV (cyclophosphamide, oral semustine, etoposide; n = 12), CEAC (oral semustine, etoposide, cytarabine, cyclophosphamide; n = 16), or SEAM (oral semustine, etoposide, cytarabine, melphalan; n = 36). Multivariate Cox analysis identified pre-transplant partial remission as an independent adverse prognostic factor for PFS (HR: 4.864; 95% CI: 1.094-21.634, p = 0.038). Although the four carmustine-substituted conditioning regimens demonstrated similar efficacy outcomes for ASCT in lymphoma patients, their distinct toxicity profiles highlight the need for personalized regimen selection, particularly in the context of carmustine shortages."

Journal • Real-world evidence • Cardiovascular • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Oncology • Transplantation

TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) and trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC). (ASCO 2026) - P2 | "Funded by pfizer, Women's Cancer Institute of Institut Curie Clinical Trial Registration Number: NCT05955170 Background: Patients with HER2-positive metastatic breast cancer (HER2+ MBC) have limited therapeutic options after progression on tucatinib–trastuzumab–capecitabine. A total of 55 evaluable patients is planned. As of 01.2026, the safety run-in phase has been completed and enrollment into the expansion phase is ongoing."

Clinical • Combination therapy • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • TOP2A

Orbital Fungating Mass as a Rare Manifestation of Retinoblastoma: A Case Study in Palliative Care. (PubMed, Am J Case Rep) - "After 6 cycles of vincristine, etoposide, and carboplatin (VEC) chemotherapy, eye protrusion and nutritional status were improving...After oral etoposide, she developed leg pain and a left temporal lump. She is currently receiving alternating VEC and vincristine, doxorubicin, and cyclophosphamide (VDC) chemotherapy, with palliative radiotherapy, resulting in a prolonged palliative response...Delivered within a long-term palliative framework, underscoring the importance of individualized therapeutic sequencing and adapted to social constraints, this approach can prolong survival, preserve comfort, and enhance quality of life. The national screening programs enabling early retinoblastoma detection through a multidisciplinary approach are needed to prevent loss to follow-up."

Journal • Eye Cancer • Ocular Melanoma • Oncology • Pain • Palliative care • Retinal Disorders • Retinoblastoma • Solid Tumor

Title results of the safety run-in part of the TUC-TOC phase II trial (NCT05955170): Tucatinib in combination with oral etoposide (VP16) - trastuzumab in patients with metastatic HER2-positive breast cancer (HER2+ mBC) (ESMO-BC 2026) - P2 | "Background: Tucatinib combined with capecitabine and trastuzumab is a standard therapy for HER2+ mBC; data on tucatinib rechallenge are lacking...The primary endpoint of the safety run-in was the rate of dose-limiting toxicities (DLTs) among the first six evaluable patients receiving oral VP16 50 mg (days 1–14, q3w), subcutaneous trastuzumab 600 mg q3w, and oral tucatinib 300 mg twice daily... The TUC-TOC safety run-in demonstrated a favorable safety profile, supporting continuation of the trial. The primary efficacy endpoint, best objective response rate within the first 6 months, will be reported after enrollment of 55 evaluable patients."

Clinical • Combination therapy • Metastases • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2 • TOP2A

Stability studies of etoposide as syringes for intrathecal administration and syringes for pediatric oral administration. (PubMed, J Oncol Pharm Pract) - "All relevant parameters were also studied (particle contamination, pH, leachables, but also preservative efficacy and benzaldehyde content for oral etoposide and endotoxin for intrathecal etoposide.Results10 mg.mL-1 etoposide for oral administration, both in normal saline or in dextrose 5% was proven to be stable for 15 days when stored at 25°C/60% RH and 90 days at 2-8°C. Etoposide 0.1 mg·mL-1 for intrathecal administration in normal saline should be compounded in NRFit® syringes and can be stored for 14 days under refrigerated conditions. This study demonstrates that the container-closure system is an integral component of the drug product, as syringe type significantly influences impurity formation and leachable release, with direct implications for pharmaceutical quality and safety."

Journal • Pediatrics

Efficacy and safety of multimodality therapy stratified by resection rate and molecular markers in children and adolescents with ependymoma: JCCG EPN23 protocol. (PubMed, Jpn J Clin Oncol) - "JCCG EPN23 aims to optimize therapeutic strategies for pediatric ependymoma by integrating molecular classification with risk-adapted treatment. The results are expected to inform future treatment protocols and improve survival while minimizing long-term morbidity."

Biomarker • Journal • Brain Cancer • Ependymoma • Oncology • Pediatrics • Solid Tumor

Good Outcome in Patients With Relapsed Metastatic Rhabdoid Tumors Treated With Multimodal Therapy (ASPHO 2026) - "Following left nephrectomy, he was treated with 9 cycles of VDC chemotherapy (Vincristine/Doxorubicin/Cyclophosphamide)and left flank irradiation(10.8 GY) for local tumor control...He was then treated with then 5 cycles of ICE(Ifosfamide/Carboplatin/Etoposide) followed by myeloablative chemotherapy/autologous stem cell rescue with Melphalan conditioning...CSF cytology was negative for tumor cells.He then received focal posterior fossa radiation therapy (30 Gy/10 fractions) followed by 1 year of metronomic therapy with alternating oral Etoposide/Cyclophosphamide and 10 mg/kg Bevacizumab every 15 days...Following a near total tumor resection he was treated on the Hospital for Sick Children ATRT Protocol (3 × Induction cycles with intrathecal cytarabine/3 × consolidation cycle with Carboplatin/Thiotepa conditioning followed by 18 maintenance cycles with PO Tamoxifen/ PO Isotretinoin/Intrathecal Topotecan.12 months after completion of maintenance cycle18 MRI Brain..."

Clinical • Metastases • Brain Cancer • Oncology • Renal Cell Carcinoma • Rhabdoid Tumor • Sarcoma • Solid Tumor • SMARCA4 • SMARCB1

Clinical Study of Etoposide Soft Capsules Combined with Immune Checkpoint Inhibitors as Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer without Disease Progression After First-Line Chemoimmunotherapy (ChiCTR) - P=N/A | N=49 | Sponsor: Army Medical Center of PLA; Army Medical Center of PLA

Checkpoint inhibition • New trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Comparative Efficacy and Safety of Second-Line Therapies in Relapsed Small-Cell Lung Cancer: A Systematic Review and Pooled Analysis (NCCN 2026) - "Regimens were categorized as platinum rechallenge, BiTE (tarlatamab), lurbinectedin, topotecan, PD-1/PD-L1 inhibitors, temozolomide, paclitaxel, docetaxel, gemcitabine, oral etoposide, or irinotecan. Platinum rechallenge and tarlatamab provide the highest response rates, with tarlatamab yielding the longest survival and favorable tolerability. Lurbinectedin consistently outperforms topotecan, PD-1/PD-L1 therapy, and other cytotoxics across ORR, PFS, and OS, supporting its role as a preferred second-line regimen in appropriate patients. These results highlight the importance of individualized sequencing and the need for randomized head-to-head comparisons to refine the second-line SCLC treatment paradigm."

Retrospective data • Review • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Aumolertinib plus oral etoposide (Lastet) as first-line treatment for EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC): The multicenter, phase II EVOLUTION study (ELCC 2026) - P2 | "No new safety signals were identified compared with the established profiles of each individual drug.Conclusions The all-oral combination of aumolertinib and etoposide demonstrated promising antitumor activity and a manageable safety profile in treatment-naive EGFR-mutated NSCLC. This regimen offers a potential convenient, outpatient-based therapeutic strategy worthy of further validation."

Clinical • Metastases • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Retraction: A phase II, single-arm study of apatinib and oral etoposide in heavily pre-treated metastatic breast cancer. (PubMed, Front Oncol) - "[This retracts the article DOI: 10.3389/fonc.2020.565384.]."

Journal • P2 data • Breast Cancer • Oncology • Solid Tumor

Gut bacterial O-demethylation modulates systemic exposure to oral etoposide. (PubMed, Gut Microbes) - "Comparative pharmacokinetic analysis of orally administered etoposide in control and antibiotic-treated mice showed that systemic exposure to etoposide increased 1.9-fold, while M1 exposure decreased 3.7-fold in antibiotic-treated mice, suggesting that gut microbial O-demethylation is a significant determinant of etoposide metabolism and disposition. Collectively, our study reveals the prevalence of gut bacteria with O-demethylation activity, illustrates the contribution of gut microbial O-demethylation to altering drug efficacy and toxicity with the model drug etoposide, and provides a knowledge basis for in-depth characterization of other drugs identified as being susceptible to gut microbial O-demethylation."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology

Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study (clinicaltrials.gov) - P2 | N=47 | Not yet recruiting | Sponsor: The Third Affiliated Hospital of Harbin Medical University

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

A single-arm, open-label, single-center, exploratory phase II clinical study of etoposide capsules combined with bevacizumab and avelumab in the treatment of platinum-resistant or platinum-refractory ovarian cancer (ChiCTR) - P2 | N=33 | Not yet recruiting | Sponsor: Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

New P2 trial • Platinum resistant • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • MUC16